Skip to main content

Table 4 Oncological results

From: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study

  Per-nodule   
1 months    0.33
 Complete response 42.4% (81/191) 40.0% (14/35) 0.79
 Partial response 19.9% (38/191) 25.7% (9/35) 0.44
 Stable disease 34.6% (66/191) 25,7% (9/35) 0.31
 Progressive disease 3.1% (6/191) 8.6% (3/35) 0.13
 Objective response 62.3% (119/191) 65.7% (23/35) 0.70
 Disease control 96.8% (185/191) 91.4% (32/35) 0.13
3–6 months    0.14
 Complete response 45.6% (62/136) 44.8% (13/29) 0.94
 Partial response 11.8% (16/136) 27.6% (8/29) 0.03°
 Stable disease 30.1% (41/136) 20.7% (6/29) 0.31
 Progressive disease 12.5% (17/136) 6.9% (2/29) 0.39
 Objective response 57.4% (78/136) 72.4% (21/29) 0.13
 Disease control 87.5% (119/136) 93.1% (27/29) 0.39
9–12 months    0.03
 Complete response 50.6% (45/89) 68.4% (13/19) 0.24
 Partial response 3.4% (3/89) 10.5% (2/19) 0.18
 Stable disease 30.3% (27/89) 0% (0/19) 0.006
 Progressive disease 15.7% (14/89) 21.1% (4/19) 0.57
 Objective response 53.9% (48/89) 78.9% (15/19) 0.05
 Disease control 84.3% (75/89) 78.9% (15/19) 0.50
  1. CI: confidence interval; DEM-TAC: drug eluting embolics trans-arterial chemoembolization; B-TACE: balloon trans-arterial chemoembolization; LAF: last available follow-up. ° The Bonferroni’s correction in this case significantly addressed p at 0.0125 (0.05/4)